Pulnovo completes $100m financing round with Medtronic investment

Pulnovo Medical has completed an oversubscribed $100m strategical financing round, with Medtronic arsenic the pb investor.

The circular besides included information from existing investors specified arsenic EQT, Gaorong Ventures, Lilly Asia Ventures, OrbiMed and Qiming Venture Partners, on with caller investors, including HSG (formerly Sequoia China).

It marks a important infinitesimal for Pulnovo’s planetary concern growth.

The financing volition beryllium directed towards objective development, planetary regulatory submissions, planetary commercialisation, and investments successful Pulnovo’s exertion platform.

In enactment of its planetary expansion, Andre Xiao has joined arsenic main strategy officer, bringing anterior acquisition from Citadel and Millennium Management, to oversee planetary financing and strategy for Pulnovo.

Alongside the superior infusion, Pulnovo and Medtronic person signed a commercialized statement to research imaginable aboriginal commercialisation opportunities, leveraging Medtronic’s extended planetary commercialized infrastructure.

According to the companies, the statement focuses connected commercialized synergy betwixt Pulnovo and Medtronic to fortify the former’s marketplace presence.

Pulnovo’s pulmonary artery denervation (PADN) strategy addresses the underlying mechanisms of cardiopulmonary conditions and demonstrates improvements successful diligent outcomes.

The institution has carried retired astir 1,500 PADN procedures worldwide and received regulatory support successful 7 countries.

In the US, Pulnovo has received the Food and Drug Administration (FDA) breakthrough instrumentality designation and initiated 2 afloat approved investigational instrumentality exemption (IDE) trials, led by Mount Sinai elder module and prof Dr Gregg Stone.

Pulnovo chairlady and president Cynthia Chen said: “Through the integration of manufacture expertise and semipermanent capital, Pulnovo is gathering a scalable maturation exemplary anchored successful proprietary innovation, planetary objective development, and strategical ecosystem partnerships.

“This financing marks a pivotal modulation from a product-driven signifier to a afloat integrated planetary platform. As we proceed to fortify our capabilities crossed some objective and technological fronts, we stay committed to delivering meaningful innovation to patients worldwide.”

In March 2025, Pulnovo Medical closed a Series C financing round, securing $100m for progressing the company’s worldwide trials, planetary concern expansion, and strategical initiatives.

"Pulnovo completes $100m financing circular with Medtronic investment" was primitively created and published by Medical Device Network, a GlobalData owned brand.